Evidence map›Paper›PMID 36094949›Full record

ArticlePloS one2022

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis.

Michael Hendryx, Yi Dong, Jonas M Ndeke, Juhua Luo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Role of sodium-glucose cotransporter 2 inhibitors in liver diseases.World journal of experimental medicine · 2025
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Michael HendryxDepartment of Environmental and Occupational Health, School of Public Health, Indiana University, Bloomington, Indiana, United States of America.ORCID 0000-0002-2764-387X
Yi DongIndiana University Simon Cancer Center, Indianapolis, Indiana, United States of America.
Jonas M NdekeDepartment of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, Indiana, United States of America.
Juhua LuoDepartment of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, Indiana, United States of America.
Indiana University Bloomington · USIndiana University Health · US

Funding

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and lung cancer prognosisR03CA256238 · NCI · TRUSTEES OF INDIANA UNIVERSITY · PI LUO, JUHUA · 2021 to 2022
$159k
NCI NIH HHS R03 CA256238
6 · The paper itself

Abstract

introductionSodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of antidiabetic drugs. Emerging findings from laboratory studies indicate that SGLT2 inhibitors can improve liver function and suppress the proliferation of hepatocellular carcinoma (HCC) cells. The aim of this study was to test the hypothesis that initiation of SGLT2 inhibitors improves HCC prognosis in a human population.

methodsWe used National Surveillance, Epidemiology and End Results (SEER)-Medicare linked data in the United States to evaluate the role of SGLT2 inhibitor initiation on the survival of HCC patients. 3,185 HCC patients newly diagnosed between 2014 and 2017 aged 66 years or older with pre-existing type 2 diabetes were included and followed to the end of 2019. Information on SGLT2 inhibitor initiation was extracted from the Medicare Part D file.

resultsSGLT2 inhibitor initiation was associated with significantly lower mortality risk after adjusting for potential confounders (HR = 0.68, 95% CI = 0.54-0.86) with stronger association for longer duration of use (HR = 0.60, 95% CI = 0.41-0.88). Further, we found that SGLT2 inhibitor initiation was associated with a lower risk mortality risk ranging from 14% to 60% regardless of patient demographic variables, tumor characteristics, and cancer treatments.

conclusionOur large SEER-Medicare linked data study indicates that SGLT2 inhibitor initiation was associated with improved overall survival of HCC patients with pre-existing type 2 diabetes compared with no SGLT2 inhibitor use. Further studies are needed to confirm our findings and elucidate the possible mechanisms behind the association.

Indexed as

Carcinoma, HepatocellularDiabetes Mellitus, Type 2Liver NeoplasmsSodium-Glucose Transporter 2 InhibitorsAgedGlucoseHumansMedicarePrognosisSodiumUnited StatesGlucoseSodiumSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID36094949
PMCPMC9467321
OpenAlexW4295514438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.